Analyst Joseph Schwartz of Leerink Partners reiterated a Buy rating on Insmed (INSM – Research Report), with a price target of $85.00.Stay ...
In a report released today, Nicole Germino from Truist Financial maintained a Buy rating on Insmed (INSM – Research Report). The company’s ...
The companies want to slim their staff to cut costs against the backdrop of technological change, especially over the next ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback